Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Fecal microbiota transplantation can help reverse brain impairment in people with liver failure.
Given to those with polycystic kidney and liver diseases, the injectable drug reduced the volume of swollen livers.
Among HIV-positive people, mortality related to hepatitis B and C is falling but deaths due to NAFLD are rising.
People who took Viread were about two thirds less likely to develop HCC, but this could be related to other factors as well.
Among study participants, having such a rare genetic disease was associated with numerous health attacks.
Among those with primary biliary cholangitis, the investigational drug reduced alkaline phosphatase levels.
This is according to two studies of real-world use of the hepatitis C regimen.
Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.
This from a real-world analysis of people treated for hep C in the United States.
In a small ongoing study, the treatment showed an anti-cholestatic effect.
At the 24-week mark of a 48-week trial, the treatment showed a trend toward a lack of efficacy.
People who added ABI-H0731 saw greater viral load reductions than those who used nucleoside/nucleotide analogues alone.
A study compared treatment outcomes among those seen at standard intervals with those seen for just two clinic visits.
Researchers followed a group of teenagers over time and found that their rate of non-alcoholic fatty liver disease rose in young adulthood.
A real-world study of AbbVie’s hep C regimen Mavyret (glecaprevir/pibrentasvir) included people often excluded from clinical trials.
This finding is from a program that sought to provide blanket treatment to Iceland’s hep C population.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.